Alliance Asks Senate to Delay Vote on Heidi Overton’s FDA Bid
With the Senate health committee scheduled to consider Heidi Overton’s nomination on Wednesday, the Reproductive Freedom Alliance is urging lawmakers to postpone a decision until the new Congress takes office in January. The coalition of two dozen governors says voters should have a say through the representatives they recently elected.

The Senate Committee on Health, Education, Labor, and Pensions was still scheduled as of Tuesday afternoon to vote on whether to advance Overton’s nomination to lead the Food and Drug Administration. The panel is chaired by Sen. Bill Cassidy, a Louisiana Republican who is set to leave the Senate after losing his May primary to a Trump-backed challenger.
The alliance, which opposed Overton’s nomination in September, says she has a record of seeking to restrict abortion access, including medication abortion. Critics have also raised concerns about her views on vaccines, scientific research and the FDA’s independence.
Kayla Hancock, director of Protect Our Care’s Public Health Project, urged Cassidy to block the nomination. She criticized his vote to confirm Health and Human Services Secretary Robert F. Kennedy Jr. and warned that Overton could undermine public health and access to medication abortion. Hancock also accused Overton of supporting FDA actions involving fruit-flavored vapes marketed to children. Those claims and assessments were made by opponents of the nomination.
Robert Steinbrook, director of Public Citizen’s Health Research Group, cited Overton’s lack of managerial experience and her call for scientific journals to prioritize “conservative-based” science. He also said she opposes expanded access to medication abortion and supports separating the combined measles, mumps and rubella vaccine into individual shots.
At a virtual press conference, Sen. Patty Murray, a Washington Democrat on the HELP Committee, said Overton had not affirmed during her hearing that medication abortion is safe and effective. Murray also faulted her for past claims that the abortion pill was dangerous.
The FDA is reviewing mifepristone, one of the two drugs commonly used together for abortion care. Officials said Tuesday the review is expected to conclude by March. Kirsten Moore of the Expanding Medication Abortion Access Project said Overton should recuse herself from the review if confirmed, citing her former role with Project 2025 and concerns about agency independence.
Mini Timmaraju, president and CEO of Reproductive Freedom for All, warned that Overton could use the FDA post to restrict abortion access nationwide. The committee vote was due Wednesday morning; the alliance wants the Senate to leave the nomination to the next Congress.
Comments (0)
No comments yet. Be the first!